China Biotech Services (08037.HK) announced its interim performance. The company's owners' attributable loss decreased by 59.95% year-on-year to HK$32.06 million.

China Biotech Services (08037.HK) announced its mid-term performance for 2025, with a revenue of 38.872 million Hong Kong dollars, a year-on-year increase of 19.79%. The company's attributable loss was 32.006 million Hong Kong dollars, a year-on-year decrease of 59.95%, with a loss per share of 0.033 Hong Kong dollars.